Cargando…
The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic
The past two decades have seen important progress in access to timely, reliable, affordable, and quality-assured supplies of vaccines of global public health importance. The new vaccines developed are powerful tools to fight killers such as pneumonia, diarrhea, and cervical cancer. Global and region...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Health Organization. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585501/ http://dx.doi.org/10.1016/j.vaccine.2022.07.032 |
_version_ | 1784813507253895168 |
---|---|
author | Cernuschi, Tania Malvolti, Stefano Hall, Shanelle Debruyne, Luc Bak Pedersen, Hanne Rees, Helen Cooke, Emer |
author_facet | Cernuschi, Tania Malvolti, Stefano Hall, Shanelle Debruyne, Luc Bak Pedersen, Hanne Rees, Helen Cooke, Emer |
author_sort | Cernuschi, Tania |
collection | PubMed |
description | The past two decades have seen important progress in access to timely, reliable, affordable, and quality-assured supplies of vaccines of global public health importance. The new vaccines developed are powerful tools to fight killers such as pneumonia, diarrhea, and cervical cancer. Global and regional financing and pooled procurement have shortened the lag between access in high- and lower-income countries. The COVID-19 pandemic has shown that by addressing shortcomings and seizing opportunities, we can do even more. In response to COVID-19, vaccine development and access shifted from a sequential, risk-averse paradigm to a rapid approach with maximum compression of time to market while ensuring quality. Vast public investments and innovative technologies were key facilitators. The pandemic has shown that governments play a crucial role in investing in new vaccines and manufacturing capacity and sharing risks with industry. Despite impressive progress, equity in access remains elusive with important moral, economic, and health-related consequences. Global leaders are working on a new International Treaty for Pandemic Prevention, Preparedness, and Response. To apply the lessons of COVID-19, that treaty should include a new paradigm for access to vaccines in which governments agree to: (1).. establish early sharing of information about emerging outbreaks and early, evidence-informed strategic goals and leadership that serve the collective global health interest. (2).. shoulder risks and invest aggressively to address the needs of today and prepare for future emergencies. (3).. strengthen market preparedness by investing in new vaccine technologies, regional research, development and manufacturing hubs, and insurance; by enabling regulatory harmonization; by driving market transparency and oversight; and by ensuring that where public funds are invested there is a contractual obligation to ensure access. (4).. define principles and operational details for collaboration in times of scarcity that enable countries to protect their own citizens while ensuring that no country is left behind. This would ensure that COVID-19 catalyzes a shift toward greater access for all under Immunization Agenda 2030. |
format | Online Article Text |
id | pubmed-9585501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | World Health Organization. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95855012022-10-21 The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic Cernuschi, Tania Malvolti, Stefano Hall, Shanelle Debruyne, Luc Bak Pedersen, Hanne Rees, Helen Cooke, Emer Vaccine Article The past two decades have seen important progress in access to timely, reliable, affordable, and quality-assured supplies of vaccines of global public health importance. The new vaccines developed are powerful tools to fight killers such as pneumonia, diarrhea, and cervical cancer. Global and regional financing and pooled procurement have shortened the lag between access in high- and lower-income countries. The COVID-19 pandemic has shown that by addressing shortcomings and seizing opportunities, we can do even more. In response to COVID-19, vaccine development and access shifted from a sequential, risk-averse paradigm to a rapid approach with maximum compression of time to market while ensuring quality. Vast public investments and innovative technologies were key facilitators. The pandemic has shown that governments play a crucial role in investing in new vaccines and manufacturing capacity and sharing risks with industry. Despite impressive progress, equity in access remains elusive with important moral, economic, and health-related consequences. Global leaders are working on a new International Treaty for Pandemic Prevention, Preparedness, and Response. To apply the lessons of COVID-19, that treaty should include a new paradigm for access to vaccines in which governments agree to: (1).. establish early sharing of information about emerging outbreaks and early, evidence-informed strategic goals and leadership that serve the collective global health interest. (2).. shoulder risks and invest aggressively to address the needs of today and prepare for future emergencies. (3).. strengthen market preparedness by investing in new vaccine technologies, regional research, development and manufacturing hubs, and insurance; by enabling regulatory harmonization; by driving market transparency and oversight; and by ensuring that where public funds are invested there is a contractual obligation to ensure access. (4).. define principles and operational details for collaboration in times of scarcity that enable countries to protect their own citizens while ensuring that no country is left behind. This would ensure that COVID-19 catalyzes a shift toward greater access for all under Immunization Agenda 2030. World Health Organization. Published by Elsevier Ltd. 2022-10-21 /pmc/articles/PMC9585501/ http://dx.doi.org/10.1016/j.vaccine.2022.07.032 Text en © 2022 World Health Organization. Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Cernuschi, Tania Malvolti, Stefano Hall, Shanelle Debruyne, Luc Bak Pedersen, Hanne Rees, Helen Cooke, Emer The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic |
title | The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic |
title_full | The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic |
title_fullStr | The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic |
title_full_unstemmed | The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic |
title_short | The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic |
title_sort | quest for more effective vaccine markets – opportunities, challenges, and what has changed with the sars-cov-2 pandemic |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585501/ http://dx.doi.org/10.1016/j.vaccine.2022.07.032 |
work_keys_str_mv | AT cernuschitania thequestformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic AT malvoltistefano thequestformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic AT hallshanelle thequestformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic AT debruyneluc thequestformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic AT bakpedersenhanne thequestformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic AT reeshelen thequestformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic AT cookeemer thequestformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic AT cernuschitania questformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic AT malvoltistefano questformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic AT hallshanelle questformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic AT debruyneluc questformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic AT bakpedersenhanne questformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic AT reeshelen questformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic AT cookeemer questformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic |